PubMed Health⌕ Search

Biomedical subjects

D J Vaughn

Publications and source records attributed to D J Vaughn.

33 records · Page 2Linked to original sources

The role of adjuvant chemotherapy in the treatment of colorectal cancer.

Adjuvant therapy is clearly of great benefit for certain patients with colorectal carcinoma. Validation of new prognostic markers to further define which patients are at highest risk of recurrence will be important. Future investigation for adjuvant therapy includes incorporation of achievements made in the advanced disease setting, including biochemical modulation of 5-FU, identification of new active agents, and incorporation of immunotherapy strategies into adjuvant treatment programs. Further improvements in the treatment of these patients, even if small, may translate into important benefits, given the large number of patients presenting annually with this common cancer. As our therapeutic options broaden and improve, investigators will need to focus on quality of life and pharmacoeconomic parameters to determine which adjuvant approaches are optimal for the individual patient with colorectal cancer, as well as for society in general.

Adjuvants, Immunologic↗

A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial.

A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma. Forty-two consecutive patients were enrolled to received FLAP in this multi-institutional trial. Response, toxicity, and survival data were noted. Fifteen of 42 (36%) patients demonstrated objective responses, with two complete responses (5%) and 13 partial responses (31%). The median time to disease progression was 17 weeks, and the overall survival duration was 30 weeks. Myelosuppression was significant, requiring dose modifications, but there were no treatment-related deaths. FLAP is an active regimen in the treatment of advanced gastric and GE junction adenocarcinoma. We are presently using this regimen in the neoadjuvant setting in patients with gastric and GE junction cancers.

Adenocarcinoma↗

Aortic dissection in a patient receiving chemotherapy for Hodgkin's disease--a case report.

Cancer chemotherapy is associated with a wide range of vascular toxicities, which may be related to endothelial cell damage by these agents. The authors describe a patient with Hodgkin's disease who developed an atypical aortic dissection while receiving MOPP/ABV chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine). They would place aortic dissection on the list of potential vascular complications associated with antineoplastic agents.

Adult↗

Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium.

We performed a phase I trial of 3-hour paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (dose levels of 150, 175, 200, and 225 mg/m2) plus carboplatin dosed to an area under the concentration-time curve of 6. Sixteen patients were treated. Dose-limiting neuropathy was demonstrated in one patient each at the 175 and 200 mg/m2 dose levels. Grade 3 to 4 granulocytopenia was common; grade 3 to 4 thrombocytopenia was uncommon. The maximum tolerated dose of the regimen was not reached. Two complete and seven partial responses were demonstrated. We conclude that paclitaxel 225 mg/m2 plus carboplatin dosed to an area under the concentration-time curve of 6 can be administered to patients with advanced carcinoma of the urothelium. The regimen has encouraging preliminary activity. Phase II accrual is ongoing.

Aged↗

A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycin in advanced cancer.

In a pilot trial, we treated patients with solid tumors with 5-FU (5-fluorouracil), leucovorin (LV), and cisplatin (FLP) with Adriamycin in selected patients (FLAP). 5-FU/LV were administered weekly for 6 weeks, with cisplatin at two dose levels (and Adriamycin in some patients) at weeks 1 and 4. Nine patients received FLP; 11 received FLAP.FLP was able to be administered with a cisplatin dose of 75 mg/m2; the maximum-tolerated dose of FLAP included a cisplatin dose of 60 mg/m2. Significant toxicities included granulocytopenia, thrombocytopenia, and diarrhea. Preliminary activity was demonstrated with FLAP in patients with adenocarcinomas of the stomach and gastroesophageal (GE) junction. Ongoing trials of FLAP are underway in patients with gastric and GE junction carcinomas in the neoadjuvant and advanced disease settings.

Adult↗

Cavernous sinus syndrome in Hodgkin's disease.

Hodgkin's disease has not been reported to produce an isolated cavernous sinus syndrome, although this phenomenon is well-described in non-Hodgkin's lymphoma. We review the 16 cases of cavernous sinus syndrome caused by non-Hodgkin's lymphoma and report two patients with Hodgkin's disease in clinical remission who developed recurrent disease in the cavernous sinus. MRI revealed a mass lesion in the left cavernous sinus in each patient. Corticosteroids and radiation therapy were effective palliative measures. In both patients, recurrence in the cavernous sinus preceded other systemic evidence of recurrent Hodgkin's disease.

Adult↗

Chronic lymphocytic leukemia: an unusual cause of upper gastrointestinal hemorrhage.

In contrast to the acute leukemias, chronic lymphocytic leukemia (CLL) is a hematological malignancy with a generally good prognosis. Gastrointestinal (GI) involvement with CLL is unusual, and GI complications generally occur after malignant transformation to diffuse large cell lymphoma (Richter's syndrome). We present a case of CLL directly infiltrating the gastro-esophageal junction resulting in upper GI hemorrhage. This is only the second such case in the literature. We emphasize the consideration of direct leukemic infiltration in addition to Richter's syndrome in the differential diagnosis of GI bleeding in patients with CLL. Whereas the prognosis of Richter's syndrome is poor, CLL involvement of the GI tract may respond to treatment with chemo- or radiotherapy.

Aged↗

Nonsurgical management of recurrent colorectal cancer.

Most patients with colorectal carcinoma undergo attempts at curative surgery. However, some present with metastatic disease and many others ultimately relapse. Most recurrences of colorectal cancer are not resectable and require nonsurgical approaches such as chemotherapy and radiation therapy directed against local recurrences, hepatic metastases, and widely disseminated disease. Nonsurgical therapy for locoregional recurrence of rectal cancer can offer significant palliation. Intraarterial chemotherapy for liver metastases increases the likelihood of response compared to systemic treatments, but has little effect on survival. Extrahepatic progression and hepatic toxicity are important limitations to this regional therapy. 5-fluorouracil (5-FU) is the mainstay of systemic chemotherapy, and efforts to modulate biochemically the cytotoxic effects of 5-FU with folinic acid, phosphonacetyl-L-aspartate, interferon, and other agents have resulted in promising response rates. The different approaches to biochemical modulation are being studied in ongoing cooperative group trials. Novel approaches, including monoclonal antibody therapy, biologic modifier therapy, and gene therapy, are under investigation.

Colonic Neoplasms↗

High-dose cytarabine neurotoxicity: MR findings during the acute phase.

The authors report an acute cerebral and cerebellar syndrome in a patient treated with high-dose cytarabine. Diffuse high-intensity lesions in the central white matter on T2-weighted MR completely reversed with resolution of the clinical syndrome. Although the autopsy revealed cerebellar injury, the cerebral cortex was grossly and microscopically normal, consistent with a reversible process.

Acute Disease↗